SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Clinical trials for SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could tame skin lupus flares
Disease control Recruiting nowThis study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC